The pricing situation of pemetinib/pemetinib after its domestic launch is revealed

Pemigatinib (also known as pemigatinib, Pemigatinib), as an innovative treatment drug for unresectable locally advanced or metastatic cholangiocarcinoma, has been approved for marketing in China. The arrival of this drug provides a new treatment option for patients who have experienced limited results from traditional chemotherapy. Although the traditional gemcitabine combined with cisplatin treatment regimen can delay disease progression to a certain extent, most patients will still face the dilemma of disease worsening within 1 year after treatment.

Pemetinib is unique in that it can precisely inhibitkey proteins such as FGFR1, FGFR2 and FGFR3, which play an important role in the occurrence and development of cholangiocarcinoma. As the first targeted therapy for cholangiocarcinoma approved in the United States, the European Union, Japan, and Taiwan, Pemetinib undoubtedly brings new hope to patients with cholangiocarcinoma.

However, the pricing of this innovative drug has always been the focus of attention among patients and the medical community. Since pemetinib has been on the market for a relatively short time in China and has not yet been included in medical insurance, its price is relatively high. At present, pemetinib is mainly available in the domestic market in two specifications: 4.5 mg 14 tablets and 9 mg 14 tablets. The price of each box may be as high as 30,000 to 50,000 yuan. Such a price is undoubtedly a heavy burden for ordinary patients.

As an innovative drug for cholangiocarcinoma, pemetinib provides patients with a new treatment option, but its high price is still a major problem faced by patients. It is hoped that with the advancement of technology and policy adjustments, there will be more high-quality and low-cost pemetinib drugs for patients to choose from in the future. At the same time, it is also expected that relevant departments can speed up the inclusion of pemetinib in medical insurance to reduce the financial burden on patients.